Hepatitis B seroprevalence in HIV-infected patients consulting in a public day care unit in Bobo Dioulasso, Burkina Faso

Medecine et Maladies Infectieuses

Volumn 43, Issue 5, 2013, Pages 202-207

  Bado, G ^a   Penot, P ^a   N'Diaye, M D ^a   Amiel, C ^b   Hema, A ^a   Kamboule E B ^a   Guiard Schmid, J B ^c   Kabore N F ^a   Slama, L ^b   Bambara, A ^d   Laurent, C ^e   Sangare L ^d   Sawadogo, A B ^a  

^a HÔpital de jour   (Burkina Faso)

^b HÔPITAL TENON   (France)

^c Initiatives conseil international santé ^*  (Burkina Faso)

^d CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

HBV surface antigen; Hepatitis B; HIV HBV co infection

Indexed keywords

ALANINE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; SCREENING TEST; SEROPREVALENCE; SEX DIFFERENCE; VACCINATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BURKINA FASO; CARRIER STATE; COINFECTION; DAY CARE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84878785425     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.04.001     Document Type: Article

References (25)

1. Données OMS de juillet 2012 concernant le portage chronique de l'AgHBs. (accessed on January 7, 2013). http://www.who.int/mediacentre/factsheets/fs204/fr/index.html.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
3. Hepatitis B, World Health Organization Department of Communicable Diseases Surveillance and Response. 2002.
4. UNAIDS. Global Report: UNAIDS Report on the lobal AIDS epidemic. Geneva; 2012. 105 p.
5. Alter M.J. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003, 23:39-46.
6. Sangaré L., Sombié R., Combasséré A.W., Kouanda A., Kania D., Zerbo O., et al. Transmission anténatale du virus de l'hépatite B en zone de prévalence modérée du VIH, Ouagadougou, Burkina Faso. Bull Soc Pathol Exot 2009, 102(4):226-229.
7. Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoez A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
8. Konopnicki D., Mocroft A., de Wit S., Antunes F., Ledergerber B., Katlama C., et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593-601.
9. Nikolopoulos G.K., Paraskevis D., Hatzitheodorou E., et al. Impacts of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009, 48:1763-1771.
10. Bodsworth N., Donovan B., Nightingale B.N. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989, 160:577-582.
11. Yeni P (direction). « Prise en charge médicale des personnes infectées par le VIH. » Recommandations 2010 du groupe d'experts Co-infections par le VIH et les virus des hépatites. Flammarion; 2010.
12. Benhamou Y., Katlama C., Lunel F., et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996, 125:705-712.
13. Pietra V., et al. Prévalence des marqueurs du virus de l'hépatite B et des anticorps contre le virus de l'hépatite C parmi le personnel du District Sanitaire de Nanoro, Burkina Faso. Sci Tech Sci Sante 2008, 31:53-59.
14. Ilboudo D., Simpore J., Djeneba O., et al. Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa. Braz J Infect Dis 2010, 14(3):219-224.
15. Jobarteh M., Malfroy M., Peterson I., Jeng A., Sarge-Njie R., Alabi A., et al. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J 2010, 7:230-238.
16. N'Dri-Yoman T., et al. Occult HBV infection in untreated HIV-infected adults in CÔte d'Ivoire. Antivir Ther 2010, 15(7):1029-1034.
17. Harania R.S., Karuru J., Nelson M., Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008, 22(10):1221-1222.
18. Diop-Ndiaye H., Touré-Kane C., Etard J.F., LÔ G., Diaw P.A., Ngom-Gueye N.F., et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation. J Med Virol 2008, 80:1332-1336.
19. Geretti A.M., Patel M., Sarfo F.S., Chadwick D., Verheyen J., Fraune M., et al. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol 2010, 48(9):3223-3230.
20. Hoffmann C.J., Charalambous S., Martin D.J., Innes C., Churchyard G.J., Chaisson R.E., et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008, 47(11):1479-1485.
21. Mayaphi S.H., Roussow T.M., Masemola D.P., Olorunju S.A.S., Mphahlele M.J., Martin D.J. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S Afr Med J 2012, 102(3 Pt 1):157-162.
22. Mbendi Nlombi C., Longo-Mbenza B., Mbendi Nsukini S., Muyembe Tamfum J.J., Situakibanza Nanituma H., Vangu Ngoma D. Prevalence of HIV and HBs antigen in blood donors. Residual risk of contamination in blood recipients in East Kinshasa, Democratic Republic of the Congo. Med Trop (Mars) 2001, 61(2):139-142.
23. Alhababi F., Sallam T.A., Tong C.Y. The significance of "anti-HBc only" in the clinical virology laboratory. J Clin Virol 2003, 27(2):162-169.
24. Teresa P.R., Bernardo S., Manuel C., Alberto R., Teresa G.B., Antonio O., et al. Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. World J Gastroenterol 2009, 15(10):1237-1241.
25. Knoll A., Hartmann A., Hamoshi H., Weislmaier K., Jilg W. Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance. World J Gastroenterol 2006, 12(8):1255-1260.